Therapeutic area intelligence for Diagnostic Agent with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

Alcon Labs →

BPI Labs →

Assets

FDA →

Fluorescite →

Recent signals(4)

RegulatoryAugust 1, 2026

FDA Grants Approval for Fluorescein Sodium Application ANDA220046

The FDA has granted approval for the application ANDA220046 for Fluorescein Sodium submitted by BPI Labs.

RegulatoryJuly 22, 2026

FDA Grants Approval for Zydus Lifesciences' Fluorescein Sodium Application

The FDA has granted approval for Zydus Lifesciences' Abbreviated New Drug Application (ANDA218651) for Fluorescein Sodium.

RegulatoryJuly 11, 2026

FDA Approves ANDA for Fluorescein Sodium by BPI Labs

The FDA has approved the ANDA220046 for Fluorescein Sodium submitted by BPI Labs.

RegulatoryJune 21, 2026

FDA Approves Supplement for Fluorescite by Alcon Labs

The FDA has approved a supplemental application for Fluorescite, which contains fluorescein sodium.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.